MedTrace Logo

To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects

NCT06543459 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-08-09

No results posted yet for this study

Summary

A Concentration-QT Interval Correction (C-QTc) study of MY008211A Tablets in Healthy Subjects

Conditions

Interventions

DRUG

MY008211A tablets

Subjects of Group A receive MY008211A tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.

DRUG

Placebo

Subjects of Group A receive placebo tablets on Day 1 of both Sequence, wash-out period is 6 Days at least.

Sponsors & Collaborators

  • Wuhan Createrna Science and Technology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Haiyan Li, PhD · PI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-10
Primary Completion
2024-09-27
Completion
2024-12-13

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06543459 on ClinicalTrials.gov